Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

---

Szarek M., Steg P. G., DiCenso D., Bhatt D. L., Bittner V. A., Budaj A., ...Daha Fazla

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, cilt.12, sa.11, 2019 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 12 Sayı: 11
• Basım Tarihi: 2019
• Doi Numarası: 10.1161/circoutcomes.119.005858
• Dergi Adı: CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

Background: In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab was compared with placebo, added to high-intensity or maximum tolerated statin treatment after acute coronary syndrome in 18924 patients. Alirocumab reduced first occurrence of the primary composite end point-coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or hospitalization for unstable angina-as well as total nonfatal cardiovascular events and all-cause deaths. The present analysis determined whether alirocumab reduced total (first and subsequent) hospitalizations and death and increased days alive and out of hospital (DAOH) and percent DAOH in ODYSSEY OUTCOMES.